Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy.

Authors

Titouan Cazaubiel, Cyrille Touzeau, Laure Vincent, Karim Belhadj, Lionel Karlin, Salomon Manier, Aurore Perrot, Marie Christiane Vekemans, Perrine Moyer, Philippe Moreau, Mohamad Mohty, Judith Victor, Cyrille Hulin

Published in

Clinical lymphoma, myeloma & leukemia. Jun 14, 2026. Epub Jun 14, 2026.

Abstract

T-cell-redirecting therapies (TCRTs), including bispecific antibodies (BsAbs) and chimeric antigen receptor-T-cell therapy targeting B-cell maturation antigen (BCMA) or G-protein-coupled receptor class C group 5 member D (GPRC5D), have demonstrated significant efficacy in patients with relapsed/refractory multiple myeloma (RRMM). However, relapse remains common, highlighting the need for optimized TCRT sequencing strategies.
This retrospective multicenter study evaluated the safety and efficacy of BCMA-targeting BsAbs following prior treatment with GPRC5D-targeting BsAbs in RRMM patients.
A total of 26 patients were included, with a median follow-up of 20.35 months. The overall response rate was 58%, with a median progression-free survival (PFS) of 6.8 months and a median overall survival of 15.9 months. Responders demonstrated significantly longer PFS compared to nonresponders (not reached vs. 3.5 months, P < .001). The safety profile remained consistent with previous BCMA-targeting BsAbs, with cytokine release syndrome occurring in 50% of patients--none of whom experienced grade ≥ 3 events--and 38% developing grade ≥ 3 infections.
BCMA-targeting BsAbs offer an effective and well-tolerated treatment option for patients who have progressed after GPRC5D-targeting BsAbs, supporting the feasibility of this sequential approach as a promising strategy.

PMID:
42401497
Bibliographic data and abstract were imported from PubMed on 05 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.